Cyclerion Therapeutics, Inc. (CYCN)
Largest Insider Buys in Sector
CYCN Stock Price History Chart
CYCN Stock Performance
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also …
Insider Activity of Cyclerion Therapeutics, Inc.
Over the last 12 months, insiders at Cyclerion Therapeutics, Inc. have bought $0 and sold $0 worth of Cyclerion Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cyclerion Therapeutics, Inc. have bought $4.49M and sold $80,008 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 961,538 shares for transaction amount of $3M was made by Slate Path Capital LP (10 percent owner) on 2021‑06‑03.
List of Insider Buy and Sell Transactions, Cyclerion Therapeutics, Inc.
| 2023-08-09 | Sale | director | 8 0.0003% | $3.40 | $27 | -10.12% | ||
| 2021-06-03 | 10 percent owner | 961,538 0.1301% | $3.12 | $3M | -39.01% | |||
| 2021-06-03 | Chief Executive Officer | 823,170 0.1171% | $3.28 | $2.7M | -39.01% | |||
| 2021-06-03 | director | 96,153 0.013% | $3.12 | $299,997 | -39.01% | |||
| 2021-05-06 | Chief Executive Officer | 302,000 0.0413% | $2.43 | $733,860 | +6.43% | |||
| 2021-05-05 | Chief Executive Officer | 398,001 0.0553% | $2.53 | $1.01M | +3.92% | |||
| 2021-05-04 | Chief Executive Officer | 300,000 0.0415% | $2.29 | $687,000 | +14.22% | |||
| 2021-02-25 | Sale | Chief Medical Officer | 2,637 0.0004% | $3.99 | $10,522 | -24.61% | ||
| 2021-02-25 | Sale | Chief Financial Officer | 1,824 0.0003% | $4.00 | $7,296 | -24.61% | ||
| 2020-12-28 | Sale | President and CSO | 20,107 0.0032% | $3.01 | $60,522 | +3.68% | ||
| 2020-11-09 | Chief Innovation Officer | 125,000 0.0199% | $2.53 | $316,250 | +27.42% | |||
| 2020-11-06 | Sale | Chief Financial Officer | 3,827 0.0006% | $2.52 | $9,644 | +27.42% | ||
| 2020-02-21 | Sale | Chief Financial Officer | 3,559 0.0007% | $5.12 | $18,222 | -16.49% | ||
| 2019-12-30 | Sale | President | 25,000 0.0839% | $2.48 | $62,000 | +42.59% | ||
| 2019-12-27 | Sale | President | 25,000 0.0917% | $2.55 | $63,750 | +51.97% | ||
| 2019-11-15 | Chief Innovation Officer | 125,000 0.4616% | $1.82 | $227,500 | +114.44% | |||
| 2019-11-08 | Sale | Chief Financial Officer | 3,922 0.0155% | $2.05 | $8,040 | +103.16% | ||
| 2019-04-08 | director | 626,117 0.1105% | $16.00 | $10.02M | -46.83% | |||
| 2019-04-08 | director | 626,117 0.1105% | $16.00 | $10.02M | -46.83% | |||
| 2019-04-02 | President | 270,107 0.0504% | $14.81 | $4M | -38.92% |
Insider Historical Profitability
| Slate Path Capital LP | 10 percent owner | 7157601 264.1084% | $2.66 | 1 | 0 | <0.0001% |
| Hecht Peter M | Chief Executive Officer | 2047698 75.558% | $2.66 | 4 | 0 | <0.0001% |
| SCHULMAN AMY W | director | 604482 22.3048% | $2.66 | 1 | 0 | |
| Busch Andreas | Chief Innovation Officer | 254704 9.3983% | $2.66 | 2 | 0 | +70.93% |
| Currie Mark G | President and CSO | 251648 9.2856% | $2.66 | 1 | 3 |
Institutional Investor Ownership
| Slate Path Capital LP | $1.15M | 13.21 | 357,880 | 0% | +$0 | 0.02 | |
| Mfn Partners Management Lp | $542,272.00 | 6.25 | 169,460 | 0% | +$0 | 0.02 | |
| Tyndall Capital Partners L P | $527,286.00 | 6.08 | 164,777 | +0.21% | +$1,113.60 | 100 | |
| Fidelity Investments | $519,447.00 | 5.99 | 162,327 | -0.32% | -$1,670.40 | <0.0001 | |
| Artal Group S A | $444,656.00 | 5.13 | 138,955 | 0% | +$0 | <0.01 |